West Pharmaceutical Services INC Form 4 insider transactions
NYSE
Annette F Favorite, Sr. VP & Chief HR Officer at West Pharmaceutical Services, reported recent acquisitions and dispositions of company common stock and restricted stock units.
NYSE
West Pharmaceutical Services' CFO, Robert W. McMahon, acquired common stock through RSU vesting and subsequently sold a portion for tax obligations.
NYSE
West Pharmaceutical Services Director Janet Haugen reported the acquisition of phantom stock units and beneficial ownership of restricted stock units.
NYSE
Norman D. Finch, Jr., SVP, GC & Corporate Secretary of West Pharmaceutical Services Inc., was granted 192 restricted stock units and 459 stock options.
NYSE
West Pharmaceutical Services Director Janet Haugen reported an acquisition of phantom stock units, increasing her beneficial ownership.
NYSE
West Pharmaceutical Services' CFO, Robert W. McMahon, was granted significant equity awards, including restricted stock units and stock options, on August 11, 2025.
NYSE
Janet Haugen, a Director at West Pharmaceutical Services Inc., was awarded 58 phantom stock units on June 30, 2025, as part of her compensation package.
NYSE
Shane Alden Campbell, SVP at West Pharmaceutical Services, reports acquisition of restricted stock units and stock options.
NYSE
Form 4: West Pharmaceutical Services Director Douglas Michels Reports Acquisition of Restricted Stock Units
Director Douglas Michels reported the acquisition of 1,071 restricted stock units in West Pharmaceutical Services, Inc.
NYSE
Form 4: West Pharmaceutical Services Director Paolo Pucci Reports Acquisition of Restricted Stock Units
Director Paolo Pucci reports the acquisition of 1,071 restricted stock units in West Pharmaceutical Services, Inc.
NYSE
Form 4: West Pharmaceutical Services Director Janet Haugen Reports Acquisition and Disposal of Common Stock
Director Janet Brutschea Haugen reports changes in beneficial ownership of West Pharmaceutical Services Inc. common stock, including acquisition of restricted stock units and disposal of shares.
NYSE
Form 4: West Pharmaceutical Services Director Robert Friel Reports Acquisition of Restricted Stock Units
Robert Friel, a director at West Pharmaceutical Services, reported the acquisition of 1,071 restricted stock units on May 6, 2025.
NYSE
Form 4: Myla Lai Goldman Acquires 1,071 Shares of West Pharmaceutical Services Inc. (WST) Restricted Stock
Director Myla Lai Goldman acquired 1,071 shares of West Pharmaceutical Services Inc. restricted stock on May 6, 2025, which will vest at the next annual shareholder meeting.
NYSE
Form 4: West Pharmaceutical Services Director Molly Joseph Reports Acquisition of Restricted Stock Units
Director Molly Joseph reports acquisition of 1,071 restricted stock units in West Pharmaceutical Services.
NYSE
Thomas W. Hofmann, a director at West Pharmaceutical Services, acquired 1,071 shares of common stock on May 6, 2025.
NYSE
Form 4: West Pharmaceutical Services Director Deborah Keller Reports Acquisition of Restricted Stock Units
Director Deborah Keller reports the acquisition of 1,071 restricted stock units in West Pharmaceutical Services, Inc.
NYSE
Director William F. Feehery acquired 1,071 shares of West Pharmaceutical Services common stock through restricted stock units, as reported in a recent SEC Form 4 filing.
NYSE
Director Stephen H. Lockhart acquired 1,071 shares of restricted stock units in West Pharmaceutical Services, Inc.
NYSE
Mark A. Buthman, a director at West Pharmaceutical Services, acquired 1,071 shares of common stock on May 6, 2025.
NYSE
Director Janet Brutschea Haugen acquired phantom stock units in West Pharmaceutical Services, to be settled upon termination as a director.
NYSE
Bernard Birkett, CFO of West Pharmaceutical Services, reports the acquisition and disposal of common stock and stock options.
NYSE
Cindy Reiss-Clark, Chief Commercial Officer of West Pharmaceutical Services, reports the acquisition and disposal of company stock and stock options.
NYSE
Form 4: West Pharmaceutical Services SVP, GC & Corporate Secretary Reports Transaction in Company Stock
Kimberly Banks MacKay, SVP, GC & Corporate Secretary of West Pharmaceutical Services, reports acquisition and disposal of common stock and stock options on February 18, 2025.
NYSE
Annette Favorite, a Senior VP & Chief HR Officer at West Pharmaceutical Services, reported the acquisition and disposal of company stock and stock options on February 18, 2025.
NYSE
Chad Winters, VP and Chief Accounting Officer of West Pharmaceutical Services, reports the acquisition and disposal of common stock and stock options.
NYSE
Charles Witherspoon, VP & Treasurer of West Pharmaceutical Services, reports acquisition and disposal of common stock and stock options.
NYSE
Eric Green, President, CEO, and Board Chair of West Pharmaceutical Services, reports the acquisition and disposal of common stock and stock options.
NYSE
Director Janet Haugen acquired 247 shares of West Pharmaceutical Services common stock on December 16, 2024, as part of a restricted stock unit award.
NYSE
Director Janet Haugen acquired 424 restricted stock units of West Pharmaceutical Services, which will vest at the next annual shareholder meeting.
NYSE
Charles Witherspoon, VP & Treasurer of West Pharmaceutical Services, reports the exercise of stock options and subsequent sale of shares on October 29, 2024.